What MultiHance Treats: Main Uses and Benefits

MultiHance (gadobenate dimeglumine) is a gadolinium-based contrast agent (GBCA) that plays a supportive role in enhancing diagnostic images. It is applied in addressing conditions where symptoms that interfere with daily functioning require detailed visualization during a Magnetic Resonance Imaging (MRI) scan. This assists with maintaining functional stability by aiding in a more accurate assessment, which contributes to easing the overall symptom load.

The agent is commonly used across conditions presenting with acute episodes and situations involving heightened systemic burden. Its main therapeutic domains include enhancement for Central Nervous System (CNS) imaging (brain, spine, and associated tissues) and Magnetic Resonance Angiography (MRA) for evaluating occlusive vascular disease. MultiHance is used in settings where short-term symptomatic assistance is needed to help clarify the underlying issue.

The support it provides is considered relevant in certain clinical scenarios.

“The support provided contributes to the detection and visualization of lesions in diagnostic imaging.”

Quick Fact: Supports management of symptoms related to physical discomfort

Eligibility Scope

Population Status	Regulatory Rule	Condition/Limitation
Contraindicated	Patients with known hypersensitivity reactions to any Gadolinium-Based Contrast Agent (GBCA) must not use this medicine [FDA/EMA].	Use by intrathecal injection (spinal space) is not approved and is contraindicated [FDA].
Highly Restricted	Chronic, Severe Kidney Disease (GFR < 30 mL/min/1.73m^2) and Acute Kidney Injury (AKI).	Use must be avoided unless the diagnostic information is essential and unavailable without contrast [FDA].
Conditional Use	Patients with risk factors for reduced renal function (e.g., age > 60, diabetes) are required to undergo GFR testing before administration [FDA].	Pregnant women—use is restricted to situations where the imaging procedure is essential and cannot be delayed [FDA].
Approved Ages	Adults and Pediatric Patients, including term neonates, are eligible for use in Central Nervous System (CNS) imaging [FDA].	Safety and effectiveness have not been established in preterm neonates [FDA].
Lactation Status	Nursing Mothers are advised by the manufacturer to discontinue nursing before administration and not restart for at least 24 hours [FDA].	Hepatic impairment does not restrict use, as dose adjustment is not recommended [FDA].

---

Official Eligibility Statements: The regulatory profile is defined by an absolute contraindication based on prior GBCA hypersensitivity. Eligibility is then governed by warnings around renal impairment, classifying patients with severe kidney disease as high-risk and mandating that use must be avoided unless essential for diagnosis. Conditional use rules require GFR pre-screening for other at-risk populations. The medicine's approved use extends to adults and pediatric patients, including term neonates, for specific indications.

The official regulatory profile for MultiHance (gadobenate dimeglumine) is defined by constraints related to physical administration and patient physiological elimination, rather than documented metabolic drug-drug interactions.

Interaction Scope

Medicinal product categories with documented interactions: Medicinal products that compete for multispecific organic anion transporters (MOAT).

Specific interacting medicines (if explicitly listed): The regulatory label references drugs that are MOAT substrates or inhibitors, such as cisplatin and anthracyclines, in the context of theoretical interaction potential, particularly in patients with decreased MOAT activity.

Mechanistic basis of interactions (only if stated in label): Transporter-based drug-drug interactions are documented, resulting from potential competition for MOAT, which could prolong systemic exposure. No detectable biotransformation via common enzyme pathways (e.g., CYP enzymes) is documented.

Timing-based interaction rules (if applicable): Do not mix MultiHance with other intravenous medications or parenteral nutrition solutions. Do not administer other medications in the same intravenous line with MultiHance.

Population-specific interaction notes (if applicable): For patients with severe chronic kidney disease (GFR <30 mL/min/1.73m^2) or acute kidney injury, a sufficient period of time for elimination must be allowed prior to any re-administration.

Interaction-related restrictions: Prohibition on combining or mixing MultiHance with other solutions within the same intravenous line.

Resulting Interaction Structure

The regulatory documentation establishes mandatory procedural rules for physical separation during administration. Furthermore, the profile focuses on elimination-dependent constraints, requiring careful management of re-administration intervals in patients with impaired clearance. The potential for transporter-mediated interactions is noted as a relevant scenario, particularly when MOAT-competing products are co-administered.

Mechanism of Action: How MultiHance Works

MultiHance (gadobenate dimeglumine) functions through a multi-faceted biophysical mechanism centered on its paramagnetic properties. The Gadobenate ion shortens the longitudinal relaxation time (T1) of adjacent hydrogen protons in water molecules by generating a localized magnetic field. This core interaction results in a temporary, significant increase in signal intensity (brightness) on T1-weighted Magnetic Resonance Images, establishing the necessary image contrast.

Its mechanistic profile is enhanced by a physiochemical interaction involving weak, transient binding to human serum albumin in the blood. This binding slows the molecule’s motion, resulting in higher longitudinal relaxivity (r1) and a more pronounced signal boost compared to non-binding agents.

Furthermore, a specialized biological mechanism involves active cellular transport: the agent acts as a substrate for specific Organic Anion Transporting Polypeptide (OATP) transporters on hepatocytes. This active uptake into functioning liver cells, followed by clearance into the bile ducts, creates a functional contrast in the liver parenchyma and enables the visualization of the biliary tract during the delayed imaging phase.

How MultiHance is Used

MultiHance (gadobenate dimeglumine) is a diagnostic agent used to enhance image contrast during Magnetic Resonance Imaging (MRI) procedures. Its usage is strictly procedural.

---

Administration and Dosage Principles

MultiHance is supplied as a solution for injection and is approved for intravenous (IV) use only. It is administered as a single, weight-based dose during the diagnostic procedure. The standard dose for adults in Central Nervous System (CNS) imaging and Magnetic Resonance Angiography (MRA) is 0.1 mmol/kg body weight, which corresponds to 0.2 mL/kg of the 0.5 M solution. For MRI of the liver, certain regions may specify a 0.05 mmol/kg dose.

---

Procedural Context and Timing

Administration involves preparing the single-use solution—which must not be diluted—and delivering it as a rapid bolus intravenous injection. This injection must be immediately followed by a flush of 0.9% sodium chloride solution to ensure the entire dose is delivered. The required flush volume varies by procedure (e.g., at least 5 mL for CNS imaging; at least 20 mL for MRA).

Imaging acquisition begins immediately after the injection. For CNS scans, imaging may continue up to 60 minutes. For liver imaging, a delayed imaging phase is typically acquired between 40 and 120 minutes post-injection to capture the hepatobiliary contrast.

---

Special Population Rules

Specific dosage rules apply to certain populations. The standard 0.1 mmol/kg dose is used for pediatric patients aged two years and older. However, in patients with severe renal impairment (GFR <30 mL/min/1.73 m^2), the dose must not exceed 0.05 mmol/kg body weight, and any subsequent injection must be separated by a minimum interval of seven days.

Research evidence / Overview of studies for MultiHance

MultiHance (gadobenate dimeglumine) is a diagnostic agent, meaning the research focuses not on treating illness, but on its application in providing diagnostic clarity and image quality. Studies have been conducted to evaluate its use in specific types of scans by measuring outcomes related to image quality and diagnostic accuracy.

---

Evidence for Use in CNS (Brain and Spine) Imaging

Research was conducted using multicenter, randomized, double-blind, crossover comparison trials. This study design evaluated the agent directly against other contrast agents in patients with known or suspected lesions in the brain and spine. Research examined how the agent affected image quality and diagnostic information, exploring metrics such as the clarity of lesion borders and the extent of diagnostic information available to independent, blinded readers.

Studies report patterns in image contrast enhancement and visibility measured in the observed populations. Research describes changes measured in the quality of the image sets investigated in the study, providing group patterns observed in the visibility of tumors and other lesions with abnormal vascularity.

Primary findings are based on surrogate measures—meaning the studies focused on image quality and the reader's diagnostic preference, not on direct patient outcomes like long-term health or functional status. Furthermore, follow-up durations were limited to the short term, and there is limited information for long-term outcomes or the effects of repeated administrations.

---

Evidence for Use in Liver (Hepatobiliary) Imaging

The research base for liver imaging includes controlled clinical trials and prospective diagnostic studies. This research examined outcomes related to diagnostic accuracy in conditions involving known or suspected primary liver cancer or metastatic disease. These studies were structured to specifically evaluate the agent’s unique property of partial uptake by the liver.

Findings indicate that the agent allows for delayed imaging acquisition timepoints, enabling a specialized view of the liver architecture that was explored in the research. The primary findings are related to image interpretation, and data for certain groups, particularly those with severe, long-standing liver conditions, remain insufficient.

---

Research in Special Populations

Research was observed in special populations to ensure broad context. This section will outline the dedicated studies conducted in pediatric patients, including term neonates, across CNS and liver imaging indications. Separate, controlled pharmacokinetic studies were also conducted to evaluate the agent's elimination profile in adults with impaired renal function and compromised liver function. Findings describe group patterns related to how the agent was processed in these specific subgroups.

---

What Research Gaps and Uncertainties Remain

A key limitation is that the primary focus was on surrogate endpoints, not direct functional or symptomatic relief. Furthermore, comparative evidence is lacking in certain contexts, and there is limited information for long-term outcomes following years of administration. Studies contribute to the broader evidence landscape.

Key Studies & References

1. Public Assessment Report for paediatric studies submitted in accordance with Article 45 and 46 of Regulation (EC) No1901/2006
2. MRI Contrast Agents Go Head-to-Head: Researchers Find Greater Morphologic Information and Lesion Enhancement with Bracco's MultiHance... (MERIT Study/CNS Imaging)

Common questions about MultiHance (FAQ)

---

Q: How is MultiHance different from other contrast agents used in MRI?

The product information describes MultiHance as having distinct properties compared to other contrast agents. Official information indicates that the agent temporarily binds to proteins in the blood, which results in a stronger signal during the scan. Furthermore, it is partially absorbed by the liver, which allows for specialized imaging of the liver and biliary system.

---

Q: Can MultiHance cause a metallic taste in the mouth?

The official regulatory documents list a common side effect known as "taste perversion" or "dysgeusia." This common reaction is often described by patients as a temporary metallic or unusual taste in the mouth immediately following the injection.

---

Q: Is MultiHance safe for older patients, like those over 75?

Official regulatory documents do not specifically recommend a dosage adjustment based solely on age. However, patients over the age of 60 are identified as a population at risk for reduced kidney function, which requires assessment of kidney function (GFR testing) prior to administration.

---

Q: Does MultiHance pass into breast milk?

Official regulatory information indicates that the agent passes into breast milk. For this reason, official guidance suggests discontinuing breastfeeding before receiving the agent and resuming after 24 hours.

---

Q: Is MultiHance used in pregnant women?

Regulatory labeling states that use in pregnant women is restricted. The agent should only be used in situations where the imaging procedure is considered essential for diagnosis and cannot be postponed until after pregnancy.

---

Q: Have there been any major studies on the long-term safety of MultiHance?

Clinical research has primarily evaluated short-term outcomes related to image quality and diagnostic information. Official regulatory labeling notes that there is limited information available concerning long-term safety outcomes or the effects of repeated administrations over many years.

---

Q: Is MultiHance used to check for specific diseases or conditions?

Yes, it is approved for specific diagnostic purposes. According to the official indications, the agent is used to enhance images during MRI of the Central Nervous System (CNS) to visualize lesions, and for Magnetic Resonance Angiography (MRA) of the renal and peripheral arteries.

---

Q: Do research papers suggest MultiHance is superior for certain types of tissue?

Official research evidence does not make comparative claims against other agents. However, studies evaluated its unique property of partial uptake by the liver, which allows it to provide specialized images of the liver and biliary system for certain diagnostic assessments.

---

Q: How long does MultiHance stay in the body after the MRI?

The agent is eliminated relatively quickly, primarily through the kidneys. In healthy individuals, the mean elimination half-life is typically between 1.17 and 2.02 hours. A small percentage is also processed and eliminated through the liver and bile ducts.

---

Q: Are there any long-term effects associated with MultiHance?

Regulatory warnings note that small amounts of gadolinium, the active element, can remain in the body tissues (such as the skin and bone) for months to years. Regulatory labeling notes that studies have not established harm in patients with normal kidney function, but rare, non-specific symptoms have been reported.

---

Q: What does it mean if MultiHance is described as a 'non-ionic' agent?

Authoritative drug classifications describe the active component as a non-ionic contrast medium. This means the molecule remains uncharged when mixed in a solution. This chemical property is generally associated with specific characteristics in solution.

---

Q: What should I do if I feel dizzy or nauseous right after the injection?

Patient information guides recommend immediately alerting the medical staff or radiologist if feelings such as dizziness or nausea occur during or after the injection.

---

Q: Can MultiHance be used for MRI scans on different parts of the body?

Yes, the agent is approved for use across multiple anatomical regions. Official indications include imaging of the Central Nervous System (CNS), Magnetic Resonance Angiography (MRA) of the renal and peripheral arteries, and specialized imaging of the liver.

---

Q: Does MultiHance contain iodine, like some other contrast materials?

No, MultiHance does not contain iodine. The chemical structure of the active ingredient is defined by the element gadolinium, which is bound in a stable, chelated form.

---

Q: Is it possible to be allergic to MultiHance without knowing?

Official labeling indicates that hypersensitivity reactions are possible even if a patient has no previous history of allergies. According to the regulatory label, these reactions can occur immediately following administration or be delayed up to several hours.

---

Q: Are there special precautions for people with a history of seizures?

The agent is formally contraindicated in individuals with a known history of severe allergic reactions to any Gadolinium-Based Contrast Agent (GBCA). The official label notes a risk of seizures if the agent is mistakenly administered into the spine (intrathecally), which is not an approved route of use.

---

Q: Why might a doctor choose MultiHance over another gadolinium-based agent?

A doctor's selection is based on the diagnostic information required for the scan. Reasons often relate to the agent's unique pharmacological properties, such as its transient binding to blood proteins for stronger signal, or its partial uptake by the liver for specialized hepatobiliary imaging.

---

Q: Does the injection hurt when MultiHance is given?

While the agent itself is generally well-tolerated, common side effects can include local injection site reactions such as pain, a burning sensation, or a temporary feeling of warmth or coldness.

---

Q: Is it normal to feel a cold sensation at the injection site?

Injection site reactions are a common occurrence, and the regulatory label includes the possibility of a temporary feeling of coldness or warmth at the injection site as part of the expected reactions.

---

Q: Are there warnings about MultiHance and specific heart conditions?

Studies designed to evaluate the effect of the agent on electrical signals of the heart (such as QTc intervals) indicated minimal average changes. While the official documentation advises general caution in patients with cardiovascular disease, severe cardiac events can be a rare feature of a serious allergic reaction.

---

Q: What is the process for eliminating MultiHance from the body?

The body eliminates the agent through a two-part process. The majority of the agent is cleared through the kidneys via urination. A small percentage of the agent is also actively taken up by the liver and eliminated through the biliary route (bile ducts).

---

Q: What is the purpose of the chemical structure of MultiHance?

The active component, gadolinium, is bound in a stable, chemically 'chelated' form. This chemical structure is critical because chelation significantly reduces the toxicity that is otherwise associated with unbound gadolinium in the body.

---

Q: What is the general success rate of a scan when using MultiHance?

Clinical trials designed to evaluate this agent have shown that the enhanced scan achieved a statistically significant increase in the diagnostic sensitivity and specificity compared to scans performed without contrast. This increase in image clarity is the intended effect of using a contrast agent.

---

Q: Are there any restrictions on driving or operating machinery after getting MultiHance?

Patient information guides generally state that the agent is not expected to affect your ability to drive or operate machinery. Patients should still allow time for recovery and may wish to consult with medical staff if they feel unwell after the procedure.

---

Q: How do medical professionals decide if MultiHance is appropriate for me?

Appropriateness is determined based on official regulatory criteria. This includes confirming the agent is indicated for the type of scan needed, assessing your kidney function (GFR), and verifying you have no history of severe allergic reactions to any Gadolinium-Based Contrast Agents (GBCAs).

---

Q: Can MultiHance affect my blood pressure?

Blood pressure changes are not listed as common side effects. However, fluctuations may occur as a feature of a rare, serious allergic reaction (anaphylactoid reaction).

---

Q: Is there a maximum number of times a person can receive MultiHance?

Regulatory documents do not define a maximum lifetime number of administrations for the general population. However, the label emphasizes the need to allow a sufficient period of time for the agent to clear from the body before any re-administration, especially for patients with impaired kidney function.

---

Q: What information should I read about MultiHance before my appointment?

Official patient and regulatory guides highlight key information concerning the agent's purpose, use conditions, and important safety requirements. This information focuses primarily on the risks of allergic reactions, the need for kidney function assessment, and known eligibility conditions.

---

Q: Does MultiHance require any kind of specialized monitoring afterward?

Regulatory documents advise that patients should be kept under close supervision immediately following the injection. Monitoring for at least 15 minutes is standard because the majority of severe, acute allergic reactions typically occur within this timeframe.

MultiHance (gadobenate dimeglumine) must be stored under specific environmental and temperature conditions as defined by regulatory labeling.

Official Storage Requirements

The injection must be stored at controlled room temperature between 15 C and 25 C (59 F and 77 F), with permitted excursions up to 30 C. The vial must be protected from light and it is an explicit requirement to Do not freeze the product. For safety, the product must be stored out of the sight and reach of children.

Handling and Disposal

MultiHance is supplied as a single-use vial containing no preservatives. The solution must be visually inspected for particulate matter before use. Due to its single-use designation, the product must be administered immediately after opening. Any unused product remaining in the vial must be discarded and disposed of in accordance with local requirements for pharmaceutical waste.